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Background: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the
clinic. Everolimus/RAD001 (Afinitor®) has had limited efficacy as a solo agent but is projected to become part of
combination therapy for AI-resistant breast cancer. This study was conducted to investigate the anti-proliferative
and resistance mechanisms of everolimus in AI-resistant breast cancer cells.
Methods: In this study we utilized two AI-resistant breast cancer cell lines, MCF-7:5C and MCF-7:2A, which were
clonally derived from estrogen receptor positive (ER+) MCF-7 breast cancer cells following long-term estrogen
deprivation. Cell viability assay, colony formation assay, cell cycle analysis and soft agar anchorage-independent
growth assay were used to determine the efficacy of everolimus in inhibiting the proliferation and tumor forming
potential of MCF-7, MCF-7:5C, MCF-7:2A and MCF10A cells. Confocal microscopy and transmission electron
microscopy were used to evaluate LC3-II production and autophagosome formation, while ERE-luciferase reporter,
Western blot, and RT-PCR analyses were used to assess ER expression and transcriptional activity.
Results: Everolimus inhibited the proliferation of MCF-7:5C and MCF-7:2A cells with relatively equal efficiency to
parental MCF-7 breast cancer cells. The inhibitory effect of everolimus was due to G1 arrest as a result of
downregulation of cyclin D1 and p21. Everolimus also dramatically reduced estrogen receptor (ER) expression
(mRNA and protein) and transcriptional activity in addition to the ER chaperone, heat shock protein 90 protein
(HSP90). Everolimus restored 4-hydroxy-tamoxifen (4OHT) sensitivity in MCF-7:5C cells and enhanced 4OHT
sensitivity in MCF-7 and MCF-7:2A cells. Notably, we found that autophagy is one method of everolimus
insensitivity in MCF-7 breast cancer cell lines.
Conclusion: This study provides additional insight into the mechanism(s) of action of everolimus that can be used
to enhance the utility of mTOR inhibitors as part of combination therapy for AI-resistant breast cancer.
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Estrogen deprivation using aromatase inhibitors (AIs)
is currently the standard of care for patients with es-
trogen receptor-positive (ER+) breast cancer. Unfortu-
nately, ~30 % of breast cancer patients develop
resistance to AIs following long-term treatment [1]. The
mechanism by which AI resistance develops is still not
completely understood, however, several contributing fac-
tors have been identified including; alterations in ER sig-
naling, enhanced growth factor signaling, and imbalance
in the phosphoinositide 3-kinase/protein kinase B/mam-
malian target of rapamycin (PI3K/Akt/mTOR) pathway
[2, 3]. The activation of the PI3K/Akt/mTOR pathway is
considered clinically relevant for tumor escape from
hormone dependence in breast cancer, promoting the sur-
vival of breast cancer cells in estrogen-deprived conditions
[4]. Additionally, upregulation of the PI3K/Akt/mTOR
pathway is associated with poor outcome for breast cancer
patients and has been observed in AI-resistant breast can-
cer models [5, 6]. As a result, a variety of PI3K/Akt/
mTOR pathway inhibitors have been under study, includ-
ing everolimus/RAD001 (Afinitor®).
Everolimus is a rapamycin analog that is currently ap-
proved for treatment of metastatic breast cancer. It
inhibits the PI3K/Akt/mTOR signaling pathway by pre-
venting the phosphorylation of mTORC1, which inter-
rupts the signaling cascade and results in inhibition of
cell proliferation and growth [7]. Everolimus treatment
has shown promising anti-cancer effects in preclinical
studies; however, when used as a single agent, it does
not significantly decrease tumor size [8]. As a result, re-
cent clinical trials have focused instead on simultaneous
targeting of the PI3K/AKT/mTOR and ER pathways in
ER+ breast cancer [9–11]. The results from these trials
have been very encouraging due to significant improve-
ments in response rate and progression free survival for
both AI-sensitive and AI-resistant patients [12–14]. Sub-
sequent laboratory studies have focused on comparison
of everolimus in combination with endocrine therapies
[15, 16] as well as other PI3K/Akt/mTOR inhibitors in a
variety of breast cancer cell lines [17, 18] and these stud-
ies have reported synergy between tamoxifen or AI ther-
apy and everolimus. However, these studies have not
investigated the anti-cancer mechanisms of everolimus
alone in AI-resistant breast cancer cells.
Everolimus and other PI3K/Akt/mTOR inhibitors are
known to induce autophagy in both solid and blood tumors
[19, 20]; however, to our knowledge, the phenomenon has
not been reported in breast cancer. Autophagy allows cells
to degrade dysfunctional organelles and proteins, and re-
cycle their components. Autophagy can support tumor sur-
vival during treatment, making it a possible mechanism for
AI-resistance [21, 22]. This process is dependent upon the
cleavage of microtubule associated light chain 3 (LC3) toLC3-I and subsequent lipidation to LC3-II which allows for
final formation of the autophagosome membrane [23]. A
group of small proteins, called heat shock proteins (HSPs),
promote cell survival during stress reactions by promoting
the refolding of denatured proteins and directly regulating
autophagy. Specifically, HSP70 is thought to be required for
the induction of autophagy [24, 25] in response to inhib-
ition of the PI3K/Akt/mTOR pathway by either starvation
or rapamycin treatment [26, 27]. Another heat shock pro-
tein, HSP27, allows cells to survive a variety of cytotoxic
stimuli [28, 29] and is thought to be degraded during star-
vation and rapamycin-induced autophagy [30]. Due to the
link between drug resistance and autophagy, we hypothe-
sized that the induction of autophagy may contribute to
everolimus insensitivity in MCF-7 breast cancer cell lines.
In this study, we investigated the effects of everolimus, as
a single agent, or in combination with 4-hydroxy tamoxifen
(4-OHT) or chloroquine on cell proliferation, anchorage-
independent growth, PI3K/Akt/mTOR signaling, ER ex-
pression and transcriptional activity, LC3 turnover, and
autophagosome induction in AI-sensitive MCF-7 and AI-
resistant MCF-7:5C and MCF-7:2A breast cancer cells. We
report that everolimus exerts similar anti-proliferative ef-
fects in both the AI-sensitive and AI-resistant breast cancer
cell lines and that its inhibitory activity is associated with
G1 arrest and down regulation of ERα expression. Everoli-
mus also reverses and enhances 4OHT sensitivity during
long-term co-treatment of the AI-resistant cell lines. Lastly,
we report that autophagy is a mechanism of everolimus in-
sensitivity in MCF-7, MCF-7:5C and MCF-7:2A cells, pos-
sibly explaining the equal response of these cell lines to
treatment. The information from this study may enhance
future selection of everolimus containing combination ther-
apies for AI-resistant breast cancer.
Methods
Cell lines and culture conditions
The MCF-7 cell line [31, 32] was obtained from Dr. V.
Craig Jordan (University of Texas MD Anderson Cancer
Center, Houston) and maintained in RPMI-1640 medium
supplemented with 10 % fetal bovine serum, 2 mM glu-
tamine, Antibiotic/Antimitotic mix, MEM Non-Essential
Amino Acids (Invitrogen, Waltham, MA), and bovine in-
sulin at 6 ng/mL (Sigma Aldrich, St. Louis, MO). The
long-term estrogen deprived human breast cancer cell
lines; MCF-7:5C [31, 33] and MCF-7:2A [32, 34] were
cloned from parental MCF-7 cells following long term
(>12 months) culture in estrogen-free medium composed
of phenol red-free RPMI-1640, 10 % fetal bovine serum
treated three times with dextran-coated charcoal (SFS),
2 mM glutamine, bovine insulin at 6 ng/mL, Antibiotic/
Antimitotic mix, and MEM Non-Essential Amino Acids
(Invitrogen). The MCF10A cell line was purchased from
the American Type Tissue Culture Collection. They are
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ent Mixture F-12 (DMEM/F12) in a 1:1 mixture and
supplemented with 5 % horse serum, Antibiotic/Antimi-
totic mix (100 IU/mL penicillin, 100 μg/mL streptomycin,
25 μg/mL of Fungizone® from Invitrogen, Grand Island,
NY), 20 ng/ml EGF (Millipore), 0.5 mg/ml hydrocortisone,
100 ng/ml cholera toxin (Sigma Aldrich). All cell lines
were cultured at 37 °C under 5 % CO2. After over-
night acclimatization period, cells were cultured with
20 nM everolimus alone or in combination with
1 μM 4-hydroxytamoxifen (Sigma Aldrich) or 50 μM
Chloroquine (InvivoGen, San Diego, CA), in their
normal culture medium.
Cell viability
Cells were assayed for viability in 24-well plates using
the Cell-Titer Blue Assay Kit (Promega, Madison, WI)
per the manufacturer’s instructions. Assay plates were
kept at 37 °C in 5 % CO2 for 3 h and read at 560–590
nM on a BioTek Synergy 4 microplate reader using
the Gen 5 data analysis software (BioTek Instruments,
Winooski, VT).
Western blotting
Cells were seeded in 6-well plates, collected using a cell
scraper and suspended in RIPA buffer (Thermo Scien-
tific, Pittsburgh, PA) supplemented with protease inhibi-
tor cocktail and phosphatase inhibitor (Sigma Aldrich).
Cells were homogenized over ice by sonication. After
purification of the sample by centrifugation, protein con-
centration was determined by protein assay (Bio-Rad,
Hercules, CA). The proteins were separated by 4-12 %
SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
and electrically transferred to a polyvinylidene difluoride
membrane (Santa Cruz Biotechnology). After blocking
the membrane using 5 % non-fat milk, target proteins
were detected using either Anti-mTOR, anti-phospho-
mTOR, anti- LC3A/B (Cell Signaling, Beverly, MA),
anti-p70S6K, anti-phospho-p70S6K, anti-AKT, anti-
phospho-AKT (S473) or anti-ERα (Santa Cruz Biotechnol-
ogy) antibodies. Membranes were stripped and re-probed
for β-actin (Cell Signaling) or β-tubulin (Sigma Aldrich).
The appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody was applied and the positive bands
were detected using Amersham ECL Plus Western blot-
ting detection reagents (GE Health care, Piscataway, NJ).
In the case of LC3 analysis, cells were treated with 50 μM
chloroquine (CQ) for 24 or 48 h to allow for LC3-II accu-
mulation. Immunoreactivity was detected using anti-
mouse or anti-rabbit IgG conjugated to Dylight 680 or
800 fluorochromes (Thermo Scientific, Waltham, MA),
respectively. Blots were visualized on Odyssey imager
(LiCor, Lincoln, NE). Quantitation of immunoreactive
signals was done by densitometry using ImageJ 1.46rsoftware (NIH, Bethesda, MA). The ratio of protein ex-
pression to β-tubulin in each lane was calculated and pre-
sented relative to the respective controls within each
experiment.
Cell cycle analysis
Cells were incubated in the appropriate cell culture media
with and without drug treatment. Cells were harvested at
the indicated time points by trypsinization. They were
washed once with cold PBS and stained with 50 μg/mL
Propidium Iodide and 100 μg/mL RNase A in PBS (Invi-
trogen). Samples were analyzed using a BD FACSAria™ II
Flow Cytometer (BD, Franklin Lakes, NJ) and the data
were analyzed with FlowJo software (Ashland, OR).
Clonogenic proliferation assay
Cells were seeded at 1,000 cells per well in 6-well plate
in singe cell suspension. After 24 h acclimatization, they
were treated every three days and allowed to proliferate
and establish colonies for 9 days. Cells were stained with
0.5 % crystal violet in 1:7 acetic acid: methanol and im-
aged at 1X in a Bio-Rad ChemiDoc™ XRS+ System with
Image Lab™ Software (Bio-Rad Laboratories Inc.,
Hercules, CA). Colonies were counted and measured
using Image J software (The National Institute of Health,
Bethesda, MD).
Soft agar anchorage-independent growth assay
6-well plates were coated with 1 mL of 0.8 % agarose in
the appropriate culture media. Cells were then sus-
pended in 0.48 % agarose and immediately overlaid on
the pre-coated plates. Once the agarose was solid, 1 mL
of culture medium with or without 20 nM everolimus
was added and replaced every 4 days for 15 days. Cul-
tures were then stained with 0.005 % crystal violet in
PBS, washed with PBS until the background was clear
and imaged microscopically at 10X for measurement of
colony diameter. Plates were also imaged at 1X in a Bio-
Rad ChemiDoc™ XRS+ System with Image Lab™ Soft-
ware (Bio-Rad). Colonies were counted and measured
using Image J software (NIH).
Real time PCR
Cells were seeded in 6-well plates and allowed to
acclimatize overnight. Following 72 h treatment with 20
nM everolimus, cells were harvested by cell scraping in
RLT lysis buffer and total RNA was isolated using the
Qiagen RNeasy kit (Venlo, Limburg). First strand cDNA
synthesis was performed from 3 μg total RNA using MulV
Reverse Transcriptase (Applied Biosystems, Carlsbad, CA)
on a Bio Rad MyCycler™. RT-PCR was conducted using
the ViiA™ 7 Real-Time PCR system (Applied Biosystems)
and SYBR Green Reagent (Life Technologies, Carlsbad,
CA) with primers specific for ERα and the housekeeping
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GGTGCCAGGCTTTGT–3’, Reverse 5’–CAGGATCTC
TAG CCAGGCACAT –3’. Primers for PUM1: Forward-
TCACCGAGGCCCCTCTGAACCCTA Reverse- GGCA
GTAATCTCCTTCTGCATCCT (Integrated DNA Tech-
nologies, Coralville, Iowa). Relative ERα mRNA expression
level was determined as the ratio of the signal intensity to
that of PUM1 using the formula: 2-ΔCT. When treated
with everolimus, fold change in ERα expression was nor-
malized to PUM1 and then compared to the untreated
value for that cell line using the formula: 2-ΔΔCT.
Luciferase reporter assay
Cells were seeded in 12-well tissue culture plates over-
night for attachment before transfection. The cells were
transfected using Lipofectamine 2000™ Transfection Re-
agent (Invitrogen, San Diego) according to the manufac-
turer's recommendations. Briefly, 4 μL of Lipofectamine
2000, 0.8 μg of ERE Luciferase plasmid DNA and
0.01 μg of the pRL CMV Renilla (Promega) were diluted
individually in 250-μl aliquots of OptiMEM Reduced-
Serum Medium (Invitrogen). Cells were incubated for
24 h after transfection, and then treated with 20 nM EVE
or vehicle in complete media for 24 h. The Luciferase and
Renilla activities were measured using the dual luciferase
assay kit (Promega) according to the manufacturer's in-
structions. To confirm the specificity of the ERE Lucifer-
ase construct, EVE treated cells were also compared to
those treated with 1nM 17β-estradiol and 1nM Fulves-
trant, a pure anti-estrogen (Sigma). Relative Fluorescence
Units (RFUs) were calculated as a ratio of Luciferase to
Renilla signal intensity. The ERE Luciferase reporter
construct was a kind gift from Dr. Clodia Osipo (Loyola
University, Chicago, IL).
Immunofluorescence microscopy
Cells grown on glass coverslips were washed in PBS and
fixed with 100 % ice cold methanol for 10 min. After
permeabilization by 0.1 % Triton X-100 in PBS for
10 min, cells were incubated with 5 % normal horse
serum/PBS for 30 min, followed by incubation with ERα
or LC3B antibody, 2 μg/mL in 0.01 % Triton X-100 /PBS
overnight (Santa Cruz Biotechnology). Cells were stained
with fluorescein isothiocyanate (FITC)-conjugated la-
beled goat anti-rabbit IgG (Cell Signaling), 4 μg/mL in
PBS for 1 h, followed by coverslip mounting with the
ProLong® Gold anti-fade reagent with DAPI (Life Tech-
nologies). Samples were imaged on a Leica TCS SPE
confocal microscope in the Confocal Imaging Core at
The University of Kansas Medical Center. Images were
collected and analyzed using the Leica LAS AF Lite soft-
ware (Leica Biosystems, Nussloch, Germany). For quan-
tification, mean fluorescent intensity was determined
using Image J software on green (FITC) channel images.Electron microscopy
1 x106 cells were seeded in 6-well plates and treated
after an overnight acclimatization. After 72 h of treat-
ment cells were harvested by scraping and fixed for 24 h
at 4 °C in 0.1 M cacodylate buffer supplemented with
2 % glutaraldehyde. Samples were then processed in The
Electron Microscopy Research Laboratory at KU Med-
ical Center as follows. Briefly, cell pellets were washed in
0.1 M cacodylate buffer for 10 min, and resuspended.
Cell pellets were post fixed in 1 % osmium tetroxide
buffered in 0.1 M cacodylate, rinsed in distilled water
3X’s and then dehydrated in a graded series of ethanol
as follows: 50 %, 70 %, 80 %, 95 %, 100 %, 100 % 10 min
each step. Cells were placed into propylene oxide for
20 min, then into a 50:50 mixture of propylene oxide
and Embed 812 resin medium overnight at room
temperature. Samples were cured overnight in beem
capsules at 60 degrees and then sectioned with a dia-
mond knife on a Leica UC-7. Sections were cut at
80 nm and contrasted with uranyl acetate and lead cit-
rate and imaged on a JEOL 100CX II Transmission Elec-
tron Microscope (Tokyo, Japan).Statistical analysis
At least three separate experiments were performed for
each measurement unless otherwise indicated. All quanti-
tative data were expressed as means with error bars repre-
senting 1 standard deviation (mean ± 1SD). Comparisons
between two treatments were analyzed using a two-way
student t-test with P-value of < 0.05 considered to be statis-
tically significant. *p < 0.05, **p < 0.01, ***p < 0.001 unless
otherwise indicated.Results
Everolimus inhibits proliferation through induction of G1
arrest
We tested the anti-proliferative effect of everolimus in
two AI-resistant breast cancer cell lines, MCF-7:5C and
MCF-7:2A and their parental AI-sensitive cell line,
MCF-7. We found that everolimus inhibited the prolifer-
ation of MCF-7:5C and MCF-7:2A cells with relatively
equal efficiency compared to MCF-7 breast cancer cells
(Fig. 1a, upper panel). The IC50 values for MCF-7, MCF-
7:5C and MCF-7:2A cells were 25 nM, 38 nM and 20
nM, respectively, indicating only minor differences in
sensitivity to everolimus between these cell lines (Fig. 1a,
lower panel). Treatment with 20 nM everolimus achieved
maximal inhibition of all three cell lines (Fig. 1a) as early
as 24 h post-treatment (Fig. 1b). Additionally, the everoli-
mus mediated inhibition of proliferation could be main-
tained with treatment every three days under clonogenic
assay conditions (Fig. 1c). In contrast, everolimus had no
effect on the proliferation of the immortalized normal
Cell Line IC50 
MCF-7 25 nM ± 1.9
MCF-7:5C 38 nM ± 2.3


























































































Fig. 1 Everolimus inhibits the proliferation of AI-sensitive and AI-resistant breast cancer cells. a MCF-7, MCF-7:5C and MCF-7:2A cells were treated
with 20 nM everolimus or vehicle (control) for 72 h. The percent of viable cells after everolimus treatment was determined by cell viability assay
and compared to control. IC50 values for each of the cell lines were determined by nonlinear regression on normalized values. Values represent
means of three experiments conducted in quadruplet. b MCF-7, MCF-7:5C and MCF-7:2A cells were seeded in 24-well plates and treated with
20 nM everolimus or vehicle after overnight acclimatization (Day 0). The percentage of viable cells was determined at 24, 48, 72 and 96 h post
treatment by comparison to vehicle treated cells. c Cells were seeded in single cell suspension and allowed to proliferate for 9 days in the
presence of 20nM everolimus or vehicle (control). The plates were photographed at 1X magnification (left panel) and the number of colonies
and colony size were quantified using Image J (right panel). Bar graphs represent the data from three independent experiments in triplicate and
values are mean ± SD. ** p < 0.01
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Figure S1a and b).
Cell cycle analysis of MCF-7, MCF-7:5C, and MCF-
7:2A cells treated with everolimus indicated that the
anti-proliferative effect of the drug was due to G1 arrest.
The percentage of cells in G1 phase increased by at least
20 % in all three cells lines as early as 24 h after treat-
ment (Fig. 2a) and this persisted through 72 h (Fig. 2b).
Everolimus had no effect on the cycling of the normal
breast epithelial cell line MCF10A (Additional file 1:
Figure S1c). Additionally, we found that the expression
of cyclin D1 and p21 were significantly reduced in MCF-
7, MCF-7:5C and MCF-7:2A cells 48 and 72 h after
treatment (Fig. 2c). This data indicates that everolimusis effective at inhibiting the proliferation of breast cancer
cells due to marked induction of G1 arrest.
Everolimus reduces the anchorage-independent growth
The ability of cancer cells to grow in an anchorage-
independent manner is a critical marker of tumor form-
ing and metastatic potential. We compared the abilities
of MCF-7, MCF-7:5C and MCF-7:2A cells to grow in an
anchorage-independent manner using the soft-agar 3D
colony formation assay. We found that MCF-7:5C cells
produced three times more 3D colonies than the MCF-7
and MCF-7:2A cells. Additionally, 20 nM everolimus sig-
nificantly reduced the number of 3D colonies in all three
cell lines (Fig. 3a). The 3D colonies formed by the MCF-
Cell Line
24 Hours 48 Hours 72 Hours
Control EVE** Control EVE** Control EVE**
MCF-7 42.5 ± 4 60.7 ± 9 50.2 ± 5 62.2 ± 1 58.9 ± 1 66.1 ± 2
MCF-7:5C 48.1 ± 5 73.1 ± 6 56.5 ± 2 69.9 ± 4 57.8 ± 2 69.1 ± 4












































EVE (nM) 0           20           0           20             0            20
MCF-7 MCF-7:5C MCF-7:2A
0          20             0            20           0          20
48 Hrs 72 HrsC
Fig. 2 Everolimus induces G1 arrest. a MCF-7, MCF-7:5C and MCF-7:2A cells were treated for 24 h with 20 nM everolimus or vehicle and then
harvested by trypsinization. Samples were fixed with methanol, stained with propidium iodide and analyzed by flow cytometry. The percent of
cells in each phase of the cell cycle from a representative experiment are indicated in pie charts. b Samples from cells treated for 24, 48 and
72 h are summarized in the table. Values are means from three independent experiments analyzed in duplicate and are displayed as mean ± SD.
** p < 0.01. c Cyclin D1 and p21 expression in MCF-7, MCF-7:5C and MCF-7:2A cells following treatment with everolimus (20 nM) for 48 and 72 h
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MCF-7 and MCF-7:2A cells averages 40 and 35 μM2 re-
spectively. Upon microscopic inspection, we found that
20 nM everolimus dramatically reduced the size of 3D
colonies in all three cell lines, with the most pronounced
effect being on the MCF-7:5C cells (Fig. 3b). These data
indicate that everolimus inhibits not just the prolifera-
tion of breast cancer cells, but also their tumor forming
and metastatic potential.
Effects of everolimus on the PI3K/Akt/mTOR pathway
We also examined the effect of everolimus treatment on
the activation of the PI3K/Akt/mTOR pathway. We
found that everolimus significantly inhibited mTOR
phosphorylation as early as 30 min post treatment butnot Akt, p70S6K and 4EBP1 (Fig. 4, upper panels).
Everolimus inhibited the phosphorylation of downstream
members of the PI3K/Akt/mTOR pathway at 12 h. This
was most prominent at 24 h in MCF-7, MCF-7:5C and
MCF-7:2A cells (Fig. 4, bottom panels). 25 nM everoli-
mus was sufficient to inhibit PI3K/mTOR/Akt signaling
at 12 and 24 h but higher doses were more effective at
blocking phosphorylation. Notably, inhibition of p70S6K
phosphorylation was observed by 60 min in the AI-
sensitive MCF-7 cell line, especially with higher doses,
but not in the AI-resistant MCF-7:5C and MCF-7:2A
cells until 12 h post-treatment (Fig. 4). Reduction of
phospho- mTOR, p70S6K and Akt were maintained by
20 nM everolimus through 48 and 72 h (Additional file




































































Fig. 3 Everolimus reduces anchorage-independent growth. a MCF-7, MCF-7:5C and MCF-7:2A cells were seeded in single cell suspension within a
layer of 0.5 % agarose gel. Cells were treated with 20 nM everolimus or vehicle every 48 h for 17 days. Images were taken at 1X magnification
and the number of colonies quantified using Image J. b Images of the same wells were taken at 10X magnification and colony diameter in μm2
is shown. Bar graphs represent the data from three independent experiments in duplicate. The displayed values are mean ± SD. ** p < 0.01
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cancer cells.
Everolimus reduces estrogen receptor (ER) expression and
transcriptional activity
The activity of ER can be regulated by the PI3K/Akt/
mTOR pathway and is critical to the survival and prolif-
eration of AI-sensitive MCF-7 cells, as well as the AI-
resistant MCF-7:5C and MCF-7:2A cell lines. The
ligand-independent activity of ER maintains the growth
and survival of AI-resistant breast cancer cells [35, 36].
We found that treatment with everolimus significantly
reduced ER transcriptional activity and protein expres-
sion (Fig. 5a and b). This was compared to the action of
the pure anti-estrogen fulvestrant (Fig. 5a and b). Evero-
limus also dramatically reduced ERα mRNA expression
(Fig. 5c) in addition to protein expression of the ER
chaperone, HSP90 (Fig. 5d). Downregulation of ER ex-
pression was confirmed by immunofluorescent confocal
microscopy (Fig. 5e). Notably, there was higher ER tran-
scriptional activity in AI-resistant MCF-7:5C and MCF-
7:2A cells compared to parental MCF-7 cells, confirming
estrogen-independent ER action in the resistant cells
(Fig. 5a). Taken together, these data indicate that everoli-
mus, and therefore PI3K/Akt/mTOR signaling, is cap-
able of regulating ER expression and transcriptionalactivity in both wild-type MCF-7 cells and AI-resistant
MCF-7:5C and MCF-7:2A cells.
Everolimus reverses 4-OH tamoxifen resistance
Due to earlier studies that have found synergy between
tamoxifen and everolimus in endocrine-sensitive breast
cancer cell models and patients, we investigated the effi-
cacy of this combination in our MCF-7, MCF-7:5C and
MCF-7:2A cells. We have previously shown that the AI-
resistant MCF-7:5C cells are not responsive to 4OHT,
whereas MCF-7:2A are partially sensitive to 4OHT [36].
In this study, 1 μM 4OHT significantly inhibited the pro-
liferation of MCF-7 and MCF-7:2A cells, reducing the
number of 2D colonies by 20 % and 10 % respectively, but
had no effect on MCF-7:5C cells (Fig. 6a). Treatment with
20 nM everolimus for 9 days significantly reduced the pro-
liferation of all three cell lines, reducing colony numbers
by ~ 60 % (Fig. 6a). Co-treatment of MCF-7, MCF-7:5C
and MCF-7:2A cells with 1 μM 4OHT and 20 nM everoli-
mus reduced colony formation in MCF-7 and MCF-7:2A
cells by ~ 95 % and also had added benefit in the 4OHT-
resistant MCF-7:5C cells, bringing the anti-proliferative
effect from 60 % to 76 %. Synergy between 4OHT and
everolimus treatment was present despite reductions in
ERα expression in all three cell lines (Fig. 6b). This data
supports clinical observations that the combination of
MCF-7 MCF-7:5C MCF-7:2A
12 Hrs
0   25   50   100 0   25   50   100 0   25   50   100
MCF-7 MCF-7:5C MCF-7:2A
24 Hrs
























EVE (nM) 0   25   50   100 0   25   50   100 0   25   50   100
p-4EBP1
Fig. 4 Everolimus targets the mTOR/Akt pathway. AI-sensitive MCF-7 and AI-resistant MCF-7:5C and MCF-7:2A cells were treated with 25, 50 and
100nM everolimus. Phosphorylation of mTOR, AKT, p70s6K, 4EBP1 and total protein levels are shown at 30mins, 60mins, 12 and 24 h. Images are
representative of three independent experiments
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tients with ER+ breast cancer and can re-sensitize AI-
resistant breast cancer to endocrine therapy.
Everolimus induces autophagy in breast cancer cells,
which mediates insensitivity
We investigated whether everolimus treatment induced
autophagy in MCF-7, MCF-7:5C and MCF-7:2A cells.
We found that everolimus reduced the levels of HSP70
and HSP27 in all three cell lines (Fig. 7a). Interestingly,
everolimus also induced PARP cleavage (Fig. 7a); how-
ever, this was not associated with apoptosis by annexin
v/PI staining (data not shown). Chloroquine was used as
an autophagic flux inhibitor, and basal autophagy was
assessed with and without everolimus treatment. Both
immunofluorescent microscopy and western blot (Fig. 7b
and 7c), indicate that everolimus markedly enhancedLC3-II above basal level, respectively. A lysosomal prote-
ase inhibitor cocktail (100 μM leupeptin, 10 μg/mL pep-
statin A and 10 μg/mL e-64d for 24 h) was also used to
inhibit autophagic flux but results were not as robust as
with 50 μM chloroquine (data not shown). As further in-
dication of everolimus’ ability to induce autophagy, the
number of autophagosomes identified by electron mi-
croscopy in all three cell lines was also increased (Fig. 8a
and 8b). Combined inhibition of autophagy with 50 μM
CQ significantly improved the efficacy of everolimus
treatment on cell proliferation, indicating that autophagy
is a method of everolimus insensitivity in MCF-7 cell
lines (Fig. 8c). Under normal conditions, the MCF-7:5C
cell line displayed dilated endoplasmic reticulum, and
both AI-resistant cell lines had pleomorphic mitochon-
dria, indicating that aberrant metabolism is likely part of
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Fig. 5 Everolimus treatment inhibits estrogen receptor α expression and activity. a ER transcriptional activity after 24 h treatment of MCF-7, MCF-7:5C
and MCF-7:2A cells with 20 nM everolimus (EVE) and 1 μM fulvestrant (FUL) is demonstrated using an ERE luciferase reporter. b Corresponding
expression of estrogen receptor α (ERα) after 48 h of treatment is shown by western blot. c RT-PCR demonstrates the impact of 20 nM everolimus
on ERα mRNA production in all three cell lines after 24 h. d The effect of everolimus treatment on mTOR phosphorylation as well as HSP90 and ERα
expression is shown. e Immunofluorescent confocal microscopy illustrates the impact of 20 nM everolimus on ERα expression and localization (green).
Cell nuclei are stained with DAPI (blue). Bar graphs represent means from two independent experiments analyzed in quadruplet and are displayed as
mean ± SD. ** p < 0.01
Lui et al. BMC Cancer  (2016) 16:487 Page 9 of 15(Fig. 8a). These data suggest that MCF-7, MCF-7:5C and
MCF-7:2A cells use autophagy as a method of everoli-
mus resistance and that this response may be inhibited
to improve the efficacy of everolimus treatment in breast
cancer.
Discussion
This study was conducted to provide mechanistic in-
sights into the anti-proliferative effects of everolimus inAI-resistant MCF-7:5C and MCF-7:2A breast cancer cells,
and AI-sensitive MCF-7 cells. We found that everolimus
was equally effective against all three breast cancer cell
lines. The anti-proliferative mechanisms included down-
regulation of ER expression and transcriptional activity,
possibly through the suppression of HSP90. We also dem-
onstrated that everolimus enhanced 4OHT sensitivity in all
three cell lines. Everolimus treatment significantly induced
autophagy, which was associated with downregulation of
AControl 4OHT EVE 4OHT + EVE
MCF-7
Control 4OHT EVE 4OHT + EVE
MCF-7:5C
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Fig. 6 Everolimus enhances tamoxifen sensitivity. a MCF-7, MCF-7:5C and MCF-7:2A cells were seeded in single cell suspension and allowed to
proliferate for 9 days in the presence of 20 nM everolimus, 1 μM 4-hydroxy tamoxifen (4OHT) or vehicle for 48 h. The plates were photographed
and the number of colonies was quantified using Image J. Bar graphs represent the data from three independent experiments in triplicate and
values are mean ± SD. *p < 0.05, **p < 0.01. *** p < 0.001. b Western blot indicates the effect of each treatment on mTOR phosphorylation and
ERα, HSP90 expression and cleaved PARP
Lui et al. BMC Cancer  (2016) 16:487 Page 10 of 15HSP70 and HSP27 expression. Additionally, we confirmed
that everolimus inhibits the activation of the PI3K/Akt/
mTOR pathway, resulting in the downregulation of cyclin
D1 and p21 expression, which induced G1 arrest.
MCF-7 cells and their derivatives are more resistant to
everolimus as compared to other luminal A breast can-
cer cell lines [37, 38]. Our study is consistent with this
observation, as total inhibition of the MCF-7, MCF-7:5C
and MCF-7:2A cells did not exceed 60 %, making them
suitable to model a patient population that is not highly
sensitive to everolimus. Additionally, our IC50 values
were consistent with the frequent use of 20 nM everoli-
mus when studying MCF-7 cell lines [17, 39, 40]. The
enhanced insensitivity of the MCF-7:5C cells may be dueto increased expression of c-myc, which is thought to
confer some resistance in ER+ breast cancer [41, 42].
The slightly enhanced sensitivity of the MCF-7:2A cells
to everolimus may be related to comparatively lower
levels of PTEN [42]. It should be noted that the MCF-7
and MCF-7:2A cells are progesterone receptor-positive
(PR+), while the MCF-7:5C cells are PR-negative (PR-)
and they overexpresses interferon stimulated genes [43].
These differences do not seem to mediate any variances
in everolimus sensitivity, suggesting that the MCF-7
background of these cell lines is the most prominent de-
terminant of response.
Elevated ER expression and signaling has been ob-
served in both endocrine resistance cells and endocrine
MCF-7 MCF-7:5C MCF-7:2A
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Fig. 7 Everolimus modifies autophagic cell markers. a Inhibition of mTOR phosphorylation, downregulation of HSP70 and HSP27 as well as
induction of PARP cleavage by 20 nM everolimus are shown by western blot. b MCF-7, MCF-7:5C and MCF-7:2A cells were treated with vehicle,
20 nM everolimus, 50 μM chloroquine (CQ) or both for 24 h. LC3B is shown by immunofluorescent confocal microscopy. Punctate LC3B granules
(green) are indicated with white arrows. Cell nuclei are stained with DAPI (blue). Mean fluorescent intensity was determined using Image J. c Cells
were treated with vehicle, 20 nM everolimus, 50 μM chloroquine (CQ) or both for 48 h and LC3-I and -II assessed by western blot. The ratio of
LC3-II/β-Tubulin normalized to control was determined by densitometry with Image J and is shown below the blots
Lui et al. BMC Cancer  (2016) 16:487 Page 11 of 15resistant tumors [2, 3, 44, 45]. The ability of everolimus
to reduce ER transcriptional activity and phospho-ER
(p-ER) expression in MCF-7/LTED cells has been pre-
viously reported but was not assessed in wild type
MCF-7 cells [15]. In our study, we found that the in-
hibition of ER transcriptional activity was due to pro-
found downregulation of total ER expression in all cell
models. MCF-7:5C and MCF-7:2A cells are selected
clones maintained in estrogen-free media that have
retained ER transcriptional activity by upregulation of ER
expression and ligand-independent ER signaling. Incontrast, the MCF-7/LTED cells are a mixed population
of cells that have developed hypersensitivity to estrogen
[46]. Additionally, the studies by Martin and colleagues
were conducted after acute insulin deprivation, which
probably contributed to the enhanced sensitivity to evero-
limus and to the impact on both p-ER and p-Akt expres-
sion in their study. The clinical efficacy of everolimus as a
solo agent was thought to be limited by a compensatory
increase in Akt phosphorylation through mTORC2 [17].
We did not observe this reflexive increase in Akt phos-











































































Fig. 8 Everolimus treatment induces autophagy, which mediates insensitivity. a MCF-7, MCF-7:5C and MCF-7:2A cells were treated with vehicle
(a-c), 50 μM chloroquine (CQ) (d-f), 20 nM everolimus (EVE) (g-i) or both EVE and CQ (j-l) for 48 h and imaged using electron microscopy. Arrows
indicate double membrane bound autophagosomes and arrow heads indicate pleomorphic mitochondria and dilated endoplasmic reticulum,
which could also be seen in untreated MCF-7:5C cells. Images a-c are shown at 2000 X magnification while d-f, g-i and j-l are shown at 5000X,
8000X and 6000X respectively. M, mitochondria; N, nucleus; ER, endoplasmic reticulum. b Autophagosomes in a minimum of 10 random cells
were recorded using de-identified samples. Values are average autophagosomes per cell and represent three trials from two separate experiments. c
Cells were seeded in 24-well plates and treated with vehicle, 20 nM everolimus (EVE), 50 μM chloroquine or both for 7 days. The percentage of viable
cells is shown as compared to vehicle treated cells. Bar graphs represent the data from three independent experiments in duplicate and values are
mean ± SD. * p < 0.05, ** p < 0.01
Lui et al. BMC Cancer  (2016) 16:487 Page 12 of 15everolimus as a single agent has the ability to func-
tion in a manner similar to combination therapy by
inhibiting both growth factor and ER signaling simul-
taneously in some systems. Downregulation of total
ER expression by everolimus has not, to our know-
ledge, been previously reported.The downregulation of ER expression was likely due
to reduced expression of HSP90, a well-known ER
chaperone. HSP expression in general is controlled by
the PI3K/Akt/mTOR pathway through phosphorylation
of the transcription factor HSF1 and is consistent with
the loss of HSP90, HSP27 and HSP70 expression
Lui et al. BMC Cancer  (2016) 16:487 Page 13 of 15observed in this study [47]. Everolimus induced loss of
HSP90 mRNA expression has been observed in other
cancers [19] and a loss of HSP90 expression has been
linked to autophagic cell death [48]. Two HSP90 inhibi-
tors, NVP-AUY922 and STA-9090, are currently in clin-
ical trials for the treatment of breast cancer [49, 50].
HSP90 inhibitor therapy has been limited by reflexive in-
crease in HSP signaling, especially enhanced HSP27 ex-
pression [51, 52]. Here, we report that everolimus
inhibits HSP27 in our cell lines, and so may potentiate
HSP90 inhibitor treatment. These results suggest that
everolimus may be combined with HSP90 inhibitors or
drugs that target HSP90 clients for the treatment of AI-
resistant breast cancer.
AI-resistant tumors are known to retain dependence
on ER signaling for growth and survival. Given that
everolimus reduces ER expression, our observation that
it also enhances 4OHT sensitivity during long-term co-
treatment is very interesting and warrants further inves-
tigation. It should be noted, however, that everolimus
has previously been shown to inhibit ER phosphorylation
on serine 167 despite documented synergy between
everolimus and tamoxifen in AI-resistant models and
patients [10, 15, 17]. It is likely that these two drugs ex-
hibit synergy by targeting ER signaling through separate
but complementary mechanisms. Our results indicate
that everolimus reduces ER expression through inhib-
ition of ER mRNA transcription, while tamoxifen targets
the ER protein. Combining everolimus and tamoxifen
ensures that ER signaling is inhibited continuously over
time in all cells within a heterogeneous breast tumor.
The improved efficacy of everolimus in combination
with 4OHT in our study is consistent with results from
the TAMRAD clinical trial, [10]. The data from our
study suggest that everolimus could benefit AI-resistant
patients with ligand-independent ER activity by targeting
ER expression and signaling.
We have demonstrated that everolimus dramatically
induces autophagy, and is associated with significant
downregulation of HSP90, HSP70 and HSP27. Loss of
HSP70 and HSP27 is associated with starvation-induced
autophagy and rapamycin treatment, both of which tar-
get the PI3K/Akt/mTOR pathway [26, 30]. Autophagy is
a mechanism of drug insensitivity in cancer because it
allows tumors to recycle cellular components and survive
treatment [21, 22]. Inhibition of autophagy significantly
improved the anti-proliferative effects of everolimus in
MCF-7, MCF-7:5C and MCF-7:2A cells. This is consistent
with a previous study reporting enhanced inhibition of
MCF-7 cell proliferation when combining chloroquine
and everolimus [53]. Everolimus and other PI3K/Akt/
mTOR inhibitors are known to induce autophagy in both
solid and blood tumors [19, 20]; however, to our know-
ledge, this phenomenon has not been reported in breastcancer cells. We conclude that the induction of autophagy
is likely a mechanism of everolimus insensitivity in MCF-7
[37, 38], MCF-7:5C and MCF-7:2A cells.
Although everolimus treatment induced PARP cleav-
age in all three cell lines, we did not observe apoptotic
cell death normally associated with PARP cleavage.
PARP cleavage is thought to mediate autophagy rather
than apoptosis in response to certain stimuli [54]. Since
HSP70 is known to stabilize PARP [55], loss of HSP70-
mediated stability offers an explanation for the everoli-
mus induced PARP cleavage seen in this study. While
there have been reports of autophagic and apoptotic cell
death in leukemia [19] and nasopharyngeal carcinoma
cells [56], everolimus is not known to induce cell death
in breast cancer cells on its own [19, 56]. To our know-
ledge, everolimus induced cell death in breast cancer has
only been observed in aromatase expressing MCF-7/Aro
cells when combined with letrozole [7]. We have shown
that induction of autophagy limits the anti-proliferative
response of everolimus treatment, hence a combination
of everolimus with the autophagy inhibitors chloroquine
or hydroxychloroquine, which are currently in clinical
trials as part of combination therapy [57], may be benefi-
cial in the treatment of AI-resistant breast cancer.Conclusions
Overall, this study demonstrated that everolimus inhibits
the proliferation of AI-resistant breast cancer cells through
down regulation of ER expression and also that induction
of autophagy is a method of everolimus insensitivity. We
found that everolimus had similar effect on the prolifera-
tion of both our AI-sensitive (MCF-7) and AI-resistant
(MCF-7:5C and MCF-7:2A) models, suggesting that the
MCF-7 background of these cell lines overrides any other
differences that might impact everolimus sensitivity. The
inhibition of proliferation was seen regardless of PR
status, PTEN expression, type 1interferon signaling,
and 4OHT sensitivity, supporting a conclusion that
everolimus holds promise as part of combination
therapy for a wide variety of AI-resistant patients, for
whom AI treatment is not an option.Additional files
Additional file 1: Figure S1. Everolimus does not impact the
proliferation or cycling of normal breast cells. (a) MCF10A cells were
seeded in 24-well plates and treated with a range of everolimus doses in
triplicate. The percentage of viable cells was determined after 72 h of
everolimus treatment. (b) MCF10A cells were seeded in 6-well plates in
single cell suspension and treated with 20 nM everolimus for 9 days. The
number and size of clones was quantified and represents means from
two independent experiments conducted in triplicate. (c) After 24, 48
and 72 h of 20 nM everolimus treatment in 6-well plates, MCF10A cells
were subjected to cell cycle analysis. The percent of cells in G1 phase is
highlighted. (PPT 507 kb)
Lui et al. BMC Cancer  (2016) 16:487 Page 14 of 15Additional file 2: Figure S2. Everolimus targets the phosphorylation
of the PI3K/mTOR/Akt pathway at 48 and 72 h. MCF-7, MCF-7:5C and
MCF-7:2A cells were seeded in 6-well plates and treated with 25, 50 or
100 nM everolimus or vehicle. Cells were harvested at 48 and 72 h and
protein expression analyzed by western blot. Image represents three
independent experiments. (PPT 674 kb)
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